Skip to main content

EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients

Familial Cancer volume 12, pages 169–174 (2013)Cite this article

Abstract

Lynch syndrome, one of the most common cancer susceptibility syndromes, is caused by germline mutations of genes affecting the mismatch repair proteins MLH1, MSH2, MSH6 or PMS2. Most of these mutations disrupt the open reading frame of the genes involved and, as such, lead to constitutive inactivation of the mutated allele. In a subset of Lynch syndrome patients MSH2 was found to be specifically inactivated in cell lineages exhibiting EPCAM expression. These patients carry deletions of the 3′ end of the EPCAM gene, including its polyadenylation signal. Due to concomitant transcriptional read-through of EPCAM, the promoter of MSH2 15 kb further downstream becomes inactivated through hypermethylation. As these 3′ EPCAM deletions occur in the germline, this MSH2 promoter methylation (‘epimutation’) is heritable. Worldwide, numerous EPCAM 3′ end deletions that differ in size and location have been detected. The risk of colorectal cancer in carriers of such EPCAM deletions is comparable to that of MSH2 mutation carriers, and is in accordance with a high expression of EPCAM in colorectal cancer stem cells. The risk of endometrial cancer in the entire group of EPCAM deletion carriers is significantly lower than that in MSH2 mutation carriers, but the actual risk appears to be dependent on the size and location of the EPCAM deletion. These observations may have important implications for the surveillance of EPCAM deletion carriers and, thus, calls for an in-depth assessment of clinically relevant genotype-phenotype correlations and its underlying molecular mechanism(s).

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. Lynch HT, Lynch PM, Lanspa SJ et al (2009) Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 76:1–18

    PubMed  Article  CAS  Google Scholar 

  2. Charbonnier F, Baert-Desurmont S, Liang P et al (2005) The 5′ region of the MSH2 gene involved in hereditary non-polyposis colorectal cancer contains a high density of recombinogenic sequences. Hum Mutat 26:255–261

    PubMed  Article  CAS  Google Scholar 

  3. van der Klift H, Wijnen J, Wagner A et al (2005) Molecular characterization of the spectrum of genomic deletions in the mismatch repair genes MSH2, MLH1, MSH6, and PMS2 responsible for hereditary nonpolyposis colorectal cancer (HNPCC). Genes Chromosom Cancer 44:123–138

    PubMed  Article  Google Scholar 

  4. Kovacs ME, Papp J, Szentirmay Z et al (2009) Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome. Hum Mutat 30:197–203

    PubMed  Article  CAS  Google Scholar 

  5. Ligtenberg MJL, Kuiper RP, Chan TL et al (2009) Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat Genet 41:112–117

    PubMed  Article  CAS  Google Scholar 

  6. Chan TL, Yuen ST, Kong CK et al (2006) Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer. Nat Genet 38:1178–1183

    PubMed  Article  CAS  Google Scholar 

  7. Tufarelli C, Stanley JA, Garrick D et al (2003) Transcription of antisense RNA leading to gene silencing and methylation as a novel cause of human genetic disease. Nat Genet 34:157–165

    PubMed  Article  CAS  Google Scholar 

  8. Yu W, Gius D, Onyango P et al (2008) Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature 451:202–206

    PubMed  Article  CAS  Google Scholar 

  9. Venkatachalam R, Ligtenberg MJL, Hoogerbrugge N et al (2010) Germline epigenetic silencing of the tumor suppressor gene PTPRJ in early onset familial colorectal cancer. Gastroenterology 139:2221–2224

    PubMed  Article  Google Scholar 

  10. Nagasaka T, Rhees J (2010) Kloor M et al Somatic hypermethylation of MSH2 is a frequent event in Lynch Syndrome colorectal cancers. Cancer Res 70:3098–3108

    PubMed  Article  CAS  Google Scholar 

  11. Niessen RC, Hofstra RMW, Westers H et al (2009) Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosom Cancer 48:737–744

    PubMed  Article  CAS  Google Scholar 

  12. Rumilla K, Schowalter KV, Kloor M et al (2011) Frequency of deletions of EPCAM (TACSTD1) in MSH2-associated Lynch syndrome cases. J Mol Diagn 13:93–99

    PubMed  Article  CAS  Google Scholar 

  13. Hesson LB, Hitchins MP, Ward RL (2010) Epimutations and cancer predisposition: importance and mechanisms. Curr Opin Genet Dev 20:290–298

    PubMed  Article  CAS  Google Scholar 

  14. Guarinos C, Castillejo A, Barberá VM et al (2010) EPCAM germ line deletions as causes of Lynch syndrome in Spanish patients. J Mol Diagn 12:765–770

    PubMed  Article  CAS  Google Scholar 

  15. Kuiper RP, Vissers LE, Venkatachalam R et al (2011) Recurrence and variability of germline EPCAM deletions in Lynch syndrome. Hum Mutat 32:407–414

    PubMed  Article  CAS  Google Scholar 

  16. Lynch HT, Riegert-Johnson DL, Snyder C et al (2011) Lynch syndrome-associated extracolonic tumors are rare in two extended families with the same EPCAM deletion. Am J Gastroenterol 106:1829–1836

    PubMed  Article  CAS  Google Scholar 

  17. Grandval P, Baert-Desurmont S, Bonnet F et al (2012) Colon-specific phenotype in Lynch syndrome associated with EPCAM deletion. Clin Genet 82:97–99

    PubMed  Article  CAS  Google Scholar 

  18. Kloor M, Voigt AY, Schackert HK et al (2011) Analysis of EPCAM protein expression in diagnostics of Lynch syndrome. J Clin Oncol 29:223–227

    PubMed  Article  Google Scholar 

  19. Huth C, Kloor M, Voigt AY et al (2012) The molecular basis of EPCAM expression loss in Lynch syndrome-associated tumors. Mod Pathol 25:911–916

    PubMed  Article  CAS  Google Scholar 

  20. Kloor M, Huth C, Voigt AY et al (2012) Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study. Lancet Oncol 13:598–606

    PubMed  Article  CAS  Google Scholar 

  21. Munz M, Baeuerle PA, Gires O (2009) The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 69:5627–5629

    PubMed  Article  CAS  Google Scholar 

  22. Patriarca C, Macchi RM, Marschner AK et al (2012) Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat Rev 38:68–75

    PubMed  Article  CAS  Google Scholar 

  23. Gires O (2011) Lessons from common markers of tumor-initiating cells in solid cancers. Cell Mol Life Sci 68:4009–4022

    PubMed  Article  CAS  Google Scholar 

  24. Kempers MJ, Kuiper RP, Ockeloen CW et al (2011) Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol 12:49–55

    PubMed  Article  Google Scholar 

  25. Sivagnanam M, Mueller JL, Lee H et al (2008) Identification of EpCAM as the gene for congenital tufting enteropathy. Gastroenterology 135:429–437

    PubMed  Article  CAS  Google Scholar 

  26. Sivagnanam M, Schaible T, Szigeti R et al (2010) Further evidence for EpCAM as the gene for congenital tufting enteropathy. Am J Med Genet A 152A:222–224

    PubMed  Article  CAS  Google Scholar 

  27. Salomon J, Espinosa-Parrilla Y, Goulet O et al (2011) A founder effect at the EPCAM locus in Congenital Tufting Enteropathy in the Arabic Gulf. Eur J Med Genet 54:319–322

    PubMed  Article  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Human Genetics, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands

    Marjolijn J. L. Ligtenberg, Roland P. Kuiper, Ad Geurts van Kessel & Nicoline Hoogerbrugge

  2. Department of Pathology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands

    Marjolijn J. L. Ligtenberg

Authors
  1. Marjolijn J. L. Ligtenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roland P. Kuiper
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ad Geurts van Kessel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nicoline Hoogerbrugge
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marjolijn J. L. Ligtenberg.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ligtenberg, M.J.L., Kuiper, R.P., Geurts van Kessel, A. et al. EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients. Familial Cancer 12, 169–174 (2013). https://doi.org/10.1007/s10689-012-9591-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10689-012-9591-x

Keywords

  • Lynch syndrome
  • EPCAM
  • Transcriptional read-through
  • MSH2 hypermethylation
  • Transcriptional gene silencing
  • Epimutation
  • Mismatch repair gene